Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia Corp director David Johnson received a grant of 5,882 shares of common stock at no cost, reflected as a direct holding of 5,882 shares. The grant is tied to restricted stock units that convert into common stock on a one-for-one basis.
The RSUs vest upon the earlier of the one-year anniversary of the grant date or the day prior to Liquidia’s next annual shareholder meeting. Johnson is deemed to hold these securities for the benefit of Caligan-managed funds and accounts, which also indirectly hold 8,157,347 common shares.
Liquidia Corp director Raman Singh received an equity award of 5,882 shares of Common Stock as a grant with no cash paid per share. After this award, Singh directly holds 44,637 shares. The award represents restricted stock units that convert into common stock on a one-for-one basis and will vest after about a year or just before the company’s next annual shareholder meeting.
Liquidia Corp director Stephen M. Bloch reported a compensation-related equity grant. He received 5,882 shares of Common Stock at a price of $0.00 per share, recorded as a grant or award rather than an open-market purchase.
These shares arise from restricted stock units that convert into common stock on a one-for-one basis and vest upon the earlier of the one-year anniversary of the grant date or the day prior to Liquidia’s next annual shareholder meeting. Following this grant, Bloch directly holds 71,594 shares of Common Stock.
The filing also shows 980,073 shares of Common Stock held indirectly through Canaan VIII L.P. and related Canaan entities. Investment and voting decisions for these indirect holdings are made collectively by the managers of Canaan Partners VIII LLC, and Bloch disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.
Liquidia Corp director Damian deGoa received an equity grant in the form of restricted stock units that will convert into 5,882 shares of Common Stock. These RSUs were granted at no cash cost per share as part of his compensation.
After this award, deGoa directly holds 92,353 shares of Liquidia Common Stock. The RSUs convert into common stock on a one-for-one basis and will vest upon the earlier of the one-year anniversary of the grant date or the day prior to Liquidia’s next annual shareholder meeting.
Liquidia Corp director Joanna Horobin received an equity award in the form of restricted stock units. On the reported date, she was granted 5,882 RSUs, which convert into common stock on a one-for-one basis at no purchase price. After this award, she directly owns 39,637 shares of common stock. The RSUs vest upon the earlier of one year from the grant date or the day before Liquidia’s next annual shareholder meeting, tying the compensation to continued board service.
Liquidia Corp director Arthur S. Kirsch received an equity award in the form of 5,882 shares of Common Stock on June 16, 2026. The shares were acquired at a price of $0.00 per share as a compensation-related grant, not an open-market purchase.
According to footnotes, the award represents restricted stock units that convert into common stock on a one-for-one basis. The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to Liquidia’s next annual shareholder meeting. After this award, Kirsch directly holds 46,637 shares of Liquidia common stock.
Liquidia Corp director Katherine Rielly-Gauvin received a grant of 5,882 shares of common stock as an equity award. The grant is priced at $0.00 per share, reflecting a compensation-related award rather than a market purchase. After this grant, she directly holds 44,637 shares of Liquidia common stock.
The award is in the form of restricted stock units that convert into common stock on a one-for-one basis. These units will vest on the earlier of the one-year anniversary of the grant date or the day before Liquidia’s next annual shareholder meeting.
Liquidia Corp director Paul B. Manning reported an equity award of 5,882 restricted stock units (RSUs) that convert into common stock on a one-for-one basis. These RSUs vest on the earlier of one year from the grant date or the day before Liquidia’s next annual shareholder meeting. Following this grant, he directly holds 475,465 shares of common stock, with additional large direct and indirect holdings reported through joint ownership with his spouse, a revocable trust, and several investment LLCs described in the footnotes.
Liquidia Corporation reported results from its annual stockholders meeting. Shareholders elected three Class II directors to serve until the 2029 annual meeting, with David Johnson receiving 44,874,399 votes for, 58,179 withheld, and 22,546,609 broker non-votes.
Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 67,279,878 votes for, 183,739 against, and 15,570 abstentions. In a non-binding advisory vote, shareholders approved compensation for the named executive officers with 44,270,299 votes for, 612,749 against, 49,530 abstentions, and 22,546,609 broker non-votes. A quorum was present, with 67,479,187 of 88,893,621 eligible shares represented.
Liquidia Corp director-affiliated entities reported open-market sales of common stock. Entities linked to Stephen M. Bloch, primarily Canaan VIII L.P. and Canaan Partners VIII LLC, sold a total of 196,111 shares of Liquidia common stock in several open-market transactions on June 12 and June 15, 2026, at weighted average prices around $71–$72 per share. Footnotes state that Bloch disclaims beneficial ownership of securities held by the Canaan entities except for any pecuniary interest and that he did not participate in the investment decision under a communications-screen policy. Following these transactions, indirect holdings reported for the Canaan entities remained above 980,000 shares, while Bloch’s direct holding entry shows 65,712 shares as of June 12.